与PD-1、GLP-1的“热闹”相比,过去自免赛道常被贴上“冷门”标签,如今,该赛道却因IL-4Rα的密集冲刺而热度飙升。近日,康方生物、三生国健等IL-4Rα抗体迎来新进展。根据国家药品监督管理局药品审评中心(CDE)网站近日公示,康方生物自主研发的曼多奇单抗(IL-4Rα单抗,AK120)用于治疗中重度特应性皮炎的新药上市申请(NDA)已获受理。资料显示,曼多奇(AK120)是康方生物自主研发...
Source Link与PD-1、GLP-1的“热闹”相比,过去自免赛道常被贴上“冷门”标签,如今,该赛道却因IL-4Rα的密集冲刺而热度飙升。近日,康方生物、三生国健等IL-4Rα抗体迎来新进展。根据国家药品监督管理局药品审评中心(CDE)网站近日公示,康方生物自主研发的曼多奇单抗(IL-4Rα单抗,AK120)用于治疗中重度特应性皮炎的新药上市申请(NDA)已获受理。资料显示,曼多奇(AK120)是康方生物自主研发...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.